A Phase III Randomized Trial of Radiotherapy Optimization for Low-Risk HER2-Positive Breast Cancer" (HERO*)
Details
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Eligibility
You can join if...
Inclusion Criteria
-Patient must be at least 40 years of age
-Patient must have undergone breast conserving surgery and complete a minimum of 4 cycles (12 weeks) of neoadjuvant or adjuvant chemotherapy in combination with HER2-targeted therapy.
-Patient must have confirmed invasive breast carcinoma
Exclusion Criteria
-Patients with evidence of metastatic disease
-Patients planning for or status-post mastectomy
-Patients with use of any investigational product within 30 days prior to randomization